-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ASP-4901 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-4901 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-4901 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
Ventricular Tachycardia – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventricular Tachycardia - Drugs In Development, 2023’, provides an overview of the Ventricular Tachycardia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Tachycardia (Tachyarrhythmias) – Drugs In Development, 2023
Global Markets Direct’s, ‘Tachycardia (Tachyarrhythmias) - Drugs In Development, 2023’, provides an overview of the Tachycardia (Tachyarrhythmias) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tachycardia (Tachyarrhythmias), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Arrhythmias – Drugs In Development, 2023
Global Markets Direct’s, ‘Arrhythmias - Drugs In Development, 2023’, provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Systolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Systolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Systolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-740 in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-740 in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-740 in Systolic Heart Failure Drug Details: CRD-740 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-740 in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-740 in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-740 in Diastolic Heart Failure (HFpEF) Drug Details: CRD-740 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-4730 in Ventricular Tachycardia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-4730 in Ventricular Tachycardia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-4730 in Ventricular Tachycardia Drug Details: CRD-4730 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-248 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Metastatic Melanoma Drug Details: AB-248 is under development for the treatment of locally...